| HOME >> BIOLOGY >> TECHNOLOGY |
Arlington, VA (PRWEB) January 15, 2013
The growth in the stem cell market has enticed new suppliers to enter this space, and they have been successful in capturing a (small) share of the stem cell market in each of the product categories. With barriers to entry relatively low, the diversity of the stem cell market allows suppliers to offer specialized stem cell products and create a unique position in the market.
“In addition to their potential as therapeutics, stem cell biology is interesting from a research perspective, as understanding stem cell biology may lead to a better understanding of cancer,” says Nicole Camara, Ph.D., the lead science analyst on the report team. Dr. Camara also notes: “Advances in stem cell research in the last several years have also resulted in an increase in stem cell research in preclinical/clinical trials.”
Researchers have many different options for sources of stem cells in their research/work, and can obtain them from commercial suppliers, colleagues, create them in-house or obtain them directly from hospitals and patients. The BioInformatics LLC 2012 study finds that the majority of stem cell lines are currently created in-house, through colleagues, or purchased directly from commercial suppliers.
Although stem cell lines represent a much smaller share of the overall stem cell market, the study also indicates that the spending on stem cell lines continues to grow. The diversity and number of pluripotent and multipotent stem cell lines available to researchers has expanded over the past three years.
With the recent Supreme Court decision not to take up the issue, restrictions on human embryonic stem cells have loosened in the United States. Use of iPS cells has also grown worldwide. Commercial sources for characterized iPS cell lines have increased as more su
'/>"/>
| Source: PRWeb Copyright©2012 Vocus, Inc. All rights reserved |